Published in J Immunol on February 01, 1968
Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev (1983) 5.73
Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A (1977) 3.31
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun (1995) 2.87
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun (1984) 2.35
Locus of the lethal event in the serum bactericidal reaction. J Bacteriol (1968) 2.35
The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity. J Clin Invest (1976) 1.94
Failure of endotoxin to increase nonspecific resistance to infection of lipopolysaccharide low-responder mice. Infect Immun (1976) 1.71
Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrob Agents Chemother (1984) 1.67
Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol (1985) 1.67
Immunity in Experimental Salmonellosis I. Protection Induced by Rough Mutants of Salmonella typhimurium. Infect Immun (1970) 1.67
Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A (1978) 1.66
A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun (1993) 1.49
Protection against gram-negative infections with antiserum to lipid A from Salmonella minnesota R595. Infect Immun (1974) 1.47
Immunization with R mutants of Salmonella minnesota. II. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immun (1977) 1.39
Interaction of Gram-Negative Bacteria with the Lysosomal Fraction of Polymorphonuclear Leukocytes I. Role of Cell Wall Composition of Salmonella typhimurium. Infect Immun (1970) 1.34
Some galE mutants of Salmonella choleraesuis retain virulence. Infect Immun (1986) 1.34
Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest (1983) 1.28
Reduction of phagocytosis, surface hydrophobicity and charge of Salmonella typhimurium 395 MR10 by reaction with secretory IgA (SIgA). Immunology (1979) 1.25
Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med (1993) 1.22
Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine. Infect Immun (1986) 1.22
Analysis of bypass activation of C3 by endotoxic LPS and loss of this potency. Immunology (1973) 1.13
Strain-dependent cytotoxic effects of endotoxin for mouse peritoneal macrophages. Infect Immun (1978) 1.09
Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides. J Clin Invest (1973) 1.07
Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immun (1986) 1.05
A 28,000-dalton protein of normal mouse serum binds specifically to the inner core region of bacterial lipopolysaccharide. Infect Immun (1985) 1.04
Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest (1987) 1.03
Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS. Proc Natl Acad Sci U S A (2012) 0.99
Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Infect Immun (1997) 0.99
Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum. Infect Immun (2000) 0.98
Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun (1979) 0.97
Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect Immun (1992) 0.96
Salmonella choleraesuis strains deficient in O antigen remain fully virulent for mice by parenteral inoculation but are avirulent by oral administration. Infect Immun (1990) 0.91
Transfer by bone marrow cells of increased natural resistance to Klebsiella pneumoniae induced by lipopolysaccharide in genetically deficient C3H/He mice. Infect Immun (1979) 0.90
Inheritance of lipopolysaccharide-enhanced nonspecific resistance to infection and of susceptibility to endotoxic shock in lipopolysaccharide low-responder mice. Infect Immun (1977) 0.87
Immune response to parental and rough mutant strains of Salmonella minnesota. Infect Immun (1981) 0.84
Prevention of clinical coliform mastitis in dairy cows by a mutant Escherichia coli vaccine. Can J Vet Res (1989) 0.84
Enhanced vascular permeability induced in mice by larch arabinogalactan. Immunology (1970) 0.81
Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis. Mol Med (2007) 0.81
All accessible epitopes in the Salmonella lipopolysaccharide core are associated with branch residues. Infect Immun (1999) 0.78
Antimicrobial peptides for gram-negative sepsis: a case for the polymyxins. Front Immunol (2012) 0.78
alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies. Infect Immun (1998) 0.77
Proinflammatory cytokines in antilipopolysaccharide immunity against Klebsiella infections. Mediators Inflamm (2005) 0.76
On the participation of antibodies and complement in the antibacterial activity of an extract from rabbit polymorphonuclear leucocytes. Immunology (1970) 0.75
Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis. Vaccine (2015) 0.75
Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A (1977) 3.31
Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy (1978) 3.08
Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A (1976) 2.82
Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med (1988) 2.61
Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol (1979) 2.39
Mitogenic effect of bacterial peptidoglycans possessing adjuvant activity. J Immunol (1975) 2.15
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A (1975) 1.91
Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. Nature (1981) 1.85
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol (1985) 1.82
Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol (1980) 1.76
Failure of endotoxin to increase nonspecific resistance to infection of lipopolysaccharide low-responder mice. Infect Immun (1976) 1.71
Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol (1984) 1.70
Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein. Proc Natl Acad Sci U S A (1984) 1.67
Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A (1978) 1.66
Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol (1979) 1.65
Rheumatoid arthritis associated with ulcerative colitis: a case with severe flare of both diseases after delivery. Ann Rheum Dis (2001) 1.65
Blastic transformtion of mouse spleen lymphocytes by a water-soluble mitogen extracted from Nocardia. Proc Natl Acad Sci U S A (1974) 1.62
The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis (1978) 1.59
Isolation of mitogenic and adjuvant active fractions from various species of Nocardiae. Infect Immun (1975) 1.54
Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol (1982) 1.53
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
Mitogenic effect of a water-soluble extract of Nocardia opaca: a comparative study with some bacterial adjuvants on spleen and peripheral lymphocytes of four mammalian species. J Immunol (1974) 1.40
Enhancement of nonspecific immunity to bacterial infection by cord factor (6,6'-trehalose dimycolate). J Infect Dis (1977) 1.40
DNA metabarcoding multiplexing and validation of data accuracy for diet assessment: application to omnivorous diet. Mol Ecol Resour (2013) 1.39
Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol (1977) 1.36
Preparation and biological properties of water-soluble adjuvant fractions from delipidated cells of Mycobacterium smegmatis and Nocardia opaca. Infect Immun (1973) 1.35
Nonspecific activation of murine spleen cells in vitro by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine). Cell Immunol (1977) 1.35
Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. J Infect Dis (1980) 1.35
The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol (1978) 1.33
A human T-independent B lymphocyte mitogen extracted from Nocardia opaca. J Immunol (1976) 1.33
Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol (1987) 1.29
Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis (1981) 1.27
In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol (1978) 1.26
Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A (1982) 1.26
Central pyrogenic activity of muramyl dipeptide. J Exp Med (1980) 1.26
Blast transformation of rabbit B-derived lymphocytes by a mitogen extracted from Nocardia. J Immunol (1975) 1.25
Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). J Immunol (1978) 1.25
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. J Med Chem (1982) 1.25
Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant. Biochem Biophys Res Commun (1983) 1.23
Biological study of a nontoxic, water-soluble immunoadjuvant from mycobacterial cell walls. Proc Natl Acad Sci U S A (1972) 1.22
Tolerance to thyroglobulin by activating suppressor mechanisms. Ann N Y Acad Sci (1982) 1.22
[Malaria in Gabon. 2. Evaluation of the qualitative and quantitative prevalence of parasites in the total school and preschool population of the country]. Bull Soc Pathol Exot Filiales (1987) 1.22
Cell suppression in PPD-induced blast specific response of human peripheral blood lymphocytes. Clin Exp Immunol (1976) 1.18
Presence and subcellular localization of two distinct mitogenic fractions in the cells of Nocardia rubra and Nocardia opaca: preparation of soluble mitogenic peptidoglycan fractions. Infect Immun (1976) 1.18
Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res (1991) 1.18
Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan. J Exp Med (1981) 1.16
Localization and fate of 51-Cr-labeled somatic antigens of smooth and rough Salmonellae. Ann N Y Acad Sci (1966) 1.14
Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP). Ann Immunol (Paris) (1977) 1.13
The adjuvant activity of a mycobacterial water soluble adjuvant (WSA) in vitro. I. The requirement of macrophages. J Immunol (1974) 1.13
Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med (1977) 1.12
Increased resistance and depressed delayed-type hypersensitivity to Listeria monocytogenes induced by pretreatment with lipopolysaccharide. Infect Immun (1981) 1.11
Identification of Candida glabrata by a 30-second trehalase test. J Clin Microbiol (2002) 1.11
Increased permeability to choline in simian erythrocytes after Plasmodium knowlesi infection. Biochem J (1991) 1.10
Nonspecific enhancement of host defenses against infection: experimental evidence of a new order of efficacy and safety. Surgery (1981) 1.08
Nonspecific immunostimulant activities of synthetic trehalose-6,6'-diesters (lower homologs of cord factor). Infect Immun (1978) 1.08
Absence of binding of MDP, a synthetic immunoadjuvant, to anti-peptidoglycan antibodies. J Immunol (1978) 1.06
Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. J Immunol (1978) 1.06
Increased impulsive behavior and risk proneness following lentivirus-mediated dopamine transporter over-expression in rats' nucleus accumbens. Neuroscience (2008) 1.05
Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. J Exp Med (1986) 1.03
In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde. J Infect Dis (1978) 1.03
Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc (1979) 1.02
Past, present and future of the synthetic immunoadjuvant MDP and its analogs. Biochem Pharmacol (1978) 1.02
[Protective effects of bacterial immunostimulants in mice infected by "Klebsiella pneumoniae" resistant to antibiotics after mutation or by plasmid transfer]. Ann Immunol (Paris) (1975) 1.02
Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun (1987) 1.02